#United States #San Diego #Class Action #Investor Lawsuit #Hims & Hers

Opportunities for Investors in Hims & Hers Health, Inc.

Investors who acquired securities from Hims & Hers Health, Inc. (NYSE: HIMS) have been given an important opportunity to potentially lead a class action lawsuit against the company. This action comes in light of significant allegations made against Hims & Hers that suggest potential misconduct that affected the financial well-being of many investors.

Background on the Legal Action

The firm Robbins Geller Rudman & Dowd LLP has announced that individuals who purchased or acquired Hims & Hers securities during the defined Class Period, from August 4, 2025, to July 29, 2026, have until November 2, 2026, to seek the position of lead plaintiff. The case is designated as Velanki v. Hims & Hers Health, Inc., which is filed in the Northern District of California.

The primary allegations include that Hims & Hers made various misleading statements and omitted key information that could have impacted investors' decisions. Among the specific claims is that the company allegedly irresponsibly handled consumer health data and misrepresented its billing practices. The Federal Trade Commission (FTC) has also filed a complaint, further complicating the company's standing amid regulatory scrutiny.

Key Allegations

The class action lawsuit asserts that:

• - Hims & Hers shared sensitive health information from consumers with third-party advertising platforms, violating privacy protocols.
• - Consumers were charged for prescriptions nearly immediately after submitting their intake forms, contrary to claims that they would consult medical professionals regarding the most suitable treatment options.
• - Overall, Hims & Hers subjected itself to potential regulatory penalties based on these actions and public statements, which may have misled investors regarding the true state of the company.

Due to the mounting allegations, shares of Hims & Hers experienced a substantial decline of approximately 15% following the FTC's announcement.

Becoming a Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor who fits the criteria—having purchased Hims & Hers securities during the Class Period—can apply to be appointed as lead plaintiff in this lawsuit. This role is typically filled by the investor with the most significant financial interest in the litigation.

The lead plaintiff will have the responsibility of representing other class members and steering the legal strategy of the class action, and they can choose a law firm to handle the case. Nonetheless, it is essential to note that potential recovery for investors does not depend on being the lead plaintiff; participation as a class member is also available.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is prominent in the realm of securities litigation, having recovered substantial amounts for investors in recent years. The firm is known for its aggressive litigation strategies and has successfully managed many high-profile class action suits, recovering billions for investors. Investors interested in joining the lawsuit or seeking more information can directly reach out to the designated attorneys at Robbins Geller for guidance.

They can be contacted via email or by phone, facilitating a straightforward way for affected individuals to engage with the process. More details about the firm, its history, and additional insights can also be found on their official website.

In conclusion, investors of Hims & Hers Health, Inc. facing financial losses have a critical opportunity at hand. With a firm foundation for a class action lawsuit formed, timely participation could be vital in potentially recouping losses and holding relevant parties accountable for their actions.